MCID: LNG035
MIFTS: 40

Lung Large Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Rare diseases

Aliases & Classifications for Lung Large Cell Carcinoma

MalaCards integrated aliases for Lung Large Cell Carcinoma:

Name: Lung Large Cell Carcinoma 12 14
Large Cell Carcinoma of Lung 12 69
Large Cell Lung Carcinoma 12
Large Cell Lung Cancer 52

Classifications:



External Ids:

Disease Ontology 12 DOID:4556
NCIt 47 C4450
SNOMED-CT 64 254629004
UMLS 69 C0345958

Summaries for Lung Large Cell Carcinoma

MalaCards based summary : Lung Large Cell Carcinoma, also known as large cell carcinoma of lung, is related to lung cancer and lung mixed small cell and squamous cell carcinoma. An important gene associated with Lung Large Cell Carcinoma is ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and brain, and related phenotypes are Decreased viability and cardiovascular system

Wikipedia : 72 Large-cell carcinoma (LCC) is a heterogeneous group of undifferentiated malignant neoplasms that lack... more...

Related Diseases for Lung Large Cell Carcinoma

Diseases in the Lung Large Cell Carcinoma family:

Lung Clear Cell Carcinoma Small Cell Lung Cancer, Adult

Diseases related to Lung Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
id Related Disease Score Top Affiliating Genes
1 lung cancer 11.3
2 lung mixed small cell and squamous cell carcinoma 11.1
3 large cell carcinoma with rhabdoid phenotype 11.0
4 gorham's disease 10.2 DDR2 ROS1
5 large cell carcinoma 10.2
6 thrombocytosis 9.6
7 gingivitis 9.6
8 large cell neuroendocrine carcinoma 9.6
9 dermatomyositis 9.6
10 calcinosis 9.6
11 inner ear disease 9.6
12 polyarteritis nodosa 9.6
13 autoimmune inner ear disease 9.6
14 glomus tympanicum tumor 9.4 FGFR1 MTOR ROS1
15 ascariasis 5.0 ATR CASK CDC42BPB DDR2 EPHA3 EPHA5

Graphical network of the top 20 diseases related to Lung Large Cell Carcinoma:



Diseases related to Lung Large Cell Carcinoma

Symptoms & Phenotypes for Lung Large Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.95 EPHA3 MTOR
2 Decreased viability GR00221-A-1 10.95 DDR2 MTOR WNK3 FGFR1 ROS1
3 Decreased viability GR00221-A-2 10.95 DDR2 EPHA5 TTN WNK3 FGFR1 ROS1
4 Decreased viability GR00221-A-3 10.95 CDC42BPB EPHA5
5 Decreased viability GR00221-A-4 10.95 CDC42BPB DDR2 EPHA3 EPHA5 MTOR TTN
6 Decreased viability GR00301-A 10.95 EPHA3
7 Decreased viability GR00342-S-1 10.95 EPHA3 MTOR TTN ROS1
8 Decreased viability GR00342-S-2 10.95 MTOR
9 Decreased viability GR00342-S-3 10.95 EPHA5 TTN
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.46 TRRAP
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-15 10.46 CASK
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.46 TRRAP
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.46 WNK3
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.46 MTOR
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.46 WNK3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.46 TRRAP
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.46 TRRAP WNK3
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.46 MTOR
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.46 CASK MTOR TRRAP WNK3
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.46 CASK
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.46 TRRAP
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 10.46 CASK
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.46 CASK TRRAP
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 10.46 CASK
25 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.29 DDR2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.29 CASK
27 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.29 MTOR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.29 MTOR
29 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.29 CASK
30 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.29 DDR2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.29 ATR
32 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.29 NME1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.29 WNK3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.29 NME1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.29 CASK
36 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.29 DDR2 MTOR
37 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.29 ATR
38 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.29 NME1 TRRAP
39 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.29 DDR2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.29 CASK
41 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.29 CASK
42 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.29 TRRAP
43 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.29 DDR2
44 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.29 TRRAP
45 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.29 ATR
46 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.29 ATR
47 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.29 CASK
48 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.29 DDR2
49 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.29 WNK3
50 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.29 WNK3
51 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.29 DDR2
52 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.29 MTOR
53 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.29 NME1
54 Increased shRNA abundance (Z-score > 2) GR00366-A-69 10.29 WNK3
55 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.29 ATR
56 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.29 MTOR
57 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.29 DDR2
58 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.29 ATR MTOR NME1 TRRAP CASK WNK3
59 Increased shRNA abundance (Z-score > 2) GR00366-A-97 10.29 NME1
60 Decreased substrate adherent cell growth GR00193-A-1 10.21 ROS1 ATR CASK TTN
61 Decreased substrate adherent cell growth GR00193-A-2 10.21 EPHA3 MTOR ROS1 TRRAP WNK3
62 Decreased substrate adherent cell growth GR00193-A-4 10.21 CASK
63 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 10.08 ATR CDC42BPB EPHA3 FGFR1 MTOR NME1
64 Decreased cell migration GR00055-A-1 9.91 CASK CDC42BPB DDR2 EPHA3 MTOR
65 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 ATR MTOR TRRAP WNK3
66 Decreased vesicular stomatitis virus (VSV) infection GR00356-A-1 9.8 ATR CASK MTOR TRRAP TTN
67 Increased cell death HMECs cells GR00103-A-0 9.72 TTN ATR CASK FGFR1 TRRAP
68 Condensed cis-Golgi GR00365-A 9.7 FGFR1 ROS1 WNK3
69 Increased colony dispersion (increased number of colonies and decreased number of cells per colony) GR00212-A 9.55 ATR FGFR1 MTOR ROS1 TRRAP
70 Increased cell viability after pRB stimulation GR00230-A-1 9.43 CDC42BPB DDR2 WNK3
71 Transferrin accumulation in the perinuclear area GR00356-A-3 9.02 TRRAP ATR CASK FGFR1 MTOR

MGI Mouse Phenotypes related to Lung Large Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.56 ATR DDR2 EPHA3 FGFR1 MTOR MYO18B
2 mortality/aging MP:0010768 9.32 MTOR MYO18B NME1 TRRAP TTN ATR

Drugs & Therapeutics for Lung Large Cell Carcinoma

Drugs for Lung Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
3
Everolimus Approved Phase 4 159351-69-6 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
6
Armodafinil Approved, Investigational Phase 4 112111-43-0
7
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
8 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2
15 Antifungal Agents Phase 4,Phase 1,Phase 2
16 Central Nervous System Stimulants Phase 4
17 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 1
18 Wakefulness-Promoting Agents Phase 4
19
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
20
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
21
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
22
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
23
Bevacizumab Approved, Investigational Phase 2, Phase 3, Phase 1 216974-75-3
24
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
25
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
26
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
27
Vindesine Approved Phase 3 59917-39-4, 53643-48-4 40839
28
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
29
Lenograstim Approved Phase 3,Phase 2 135968-09-1
30
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
31
nivolumab Approved Phase 2, Phase 3,Phase 1 946414-94-4
32
Palbociclib Approved Phase 2, Phase 3 571190-30-2 11431660 5005498 5330286
33
Crizotinib Approved Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
34
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
36
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
37
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
38
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
39
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
40
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
41 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
42 Antimetabolites Phase 3,Phase 2,Phase 1
43 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
44 Antiviral Agents Phase 3,Phase 2,Phase 1
45 Hematinics Phase 3,Phase 2
46 Angiogenesis Inhibitors Phase 2, Phase 3, Phase 1
47 Angiogenesis Modulating Agents Phase 2, Phase 3, Phase 1
48 Antibodies Phase 2, Phase 3, Phase 1
49 Antibodies, Monoclonal Phase 2, Phase 3, Phase 1
50 Immunoglobulins Phase 2, Phase 3, Phase 1

Interventional clinical trials:

(show top 50) (show all 219)

id Name Status NCT ID Phase Drugs
1 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
2 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
3 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4 Modafinil;Placebo
4 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
5 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
6 ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures Completed NCT00404924 Phase 3 ZD6474 (vandetanib)
7 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
8 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
9 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
10 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
11 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
12 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
13 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3 carboplatin;paclitaxel
14 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
15 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
16 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
17 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
18 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
19 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
20 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
21 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
22 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
23 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
24 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer Completed NCT00312377 Phase 3 Docetaxel;Vandetanib
25 Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy Recruiting NCT02004184 Phase 3 maintenance pemetrexed;pemetrexed at progression
26 S1400 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Recruiting NCT02154490 Phase 2, Phase 3 Docetaxel;Erlotinib Hydrochloride;FGFR Inhibitor AZD4547;Palbociclib;Taselisib
27 ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients Active, not recruiting NCT02737501 Phase 3 Brigatinib;Xalkori (crizotinib)
28 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
29 Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-up Active, not recruiting NCT00198341 Phase 3
30 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
31 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
32 Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT01014130 Phase 3
33 Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Active, not recruiting NCT00324805 Phase 3 Cisplatin;Docetaxel;Gemcitabine Hydrochloride;Pemetrexed Disodium;Vinorelbine Tartrate
34 DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME Not yet recruiting NCT03321513 Phase 3 intravitreous aflibercept;Bevacizumab + Deferred Aflibercept Group
35 Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
36 Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer Terminated NCT00673049 Phase 3 CP 751,871 (Figitumumab);Erlotinib;Erlotinib
37 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
38 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
39 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
40 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
41 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
42 The Effect Of Aspirin On Survival in Lung Cancer Withdrawn NCT01058902 Phase 3 Aspirin 75 mg
43 Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
44 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
45 Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer Unknown status NCT00003492 Phase 2 antineoplaston A10;antineoplaston AS2-1
46 A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment Unknown status NCT01497041 Phase 2 Docetaxel;Oxaliplatin
47 Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
48 Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Unknown status NCT00003562 Phase 2 carboplatin;docetaxel
49 Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer Unknown status NCT00075517 Phase 2 docetaxel;gemcitabine hydrochloride
50 Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Unknown status NCT00006116 Phase 2 cisplatin;gemcitabine hydrochloride

Search NIH Clinical Center for Lung Large Cell Carcinoma

Genetic Tests for Lung Large Cell Carcinoma

Anatomical Context for Lung Large Cell Carcinoma

MalaCards organs/tissues related to Lung Large Cell Carcinoma:

39
Lung, Kidney, Brain, T Cells, Endothelial, Testes, Liver

Publications for Lung Large Cell Carcinoma

Articles related to Lung Large Cell Carcinoma:

id Title Authors Year
1
Oxidative stress associates with aggressiveness in lung large-cell carcinoma. ( 25638031 )
2015
2
Toona sinensis extracts induced cell cycle arrest and apoptosis in the human lung large cell carcinoma. ( 20123594 )
2010
3
Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. ( 20077433 )
2010
4
Lung large cell carcinoma producing granulocyte-colony-stimulating factor. ( 17184692 )
2007
5
Primary lung large cell carcinoma metastatic to the vulva: a case report and review of the literature. ( 15350382 )
2004
6
Establishment and characterization of a cell line, KaMi, from human lung large cell carcinoma. ( 1279943 )
1992

Variations for Lung Large Cell Carcinoma

Cosmic variations for Lung Large Cell Carcinoma:

9 (show top 50) (show all 524)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM21262 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 15
2 COSM12945 TTBK1 lung,NS,carcinoma,large cell carcinoma c.2417C>T p.S806F 15
3 COSM12943 TRRAP lung,NS,carcinoma,large cell carcinoma c.8015C>T p.P2672L 15
4 COSM12942 TRPM6 lung,NS,carcinoma,large cell carcinoma c.3021G>C p.W1007C 15
5 COSM10808 TP53 lung,NS,carcinoma,large cell carcinoma c.488A>G p.Y163C 15
6 COSM10687 TP53 lung,NS,carcinoma,large cell carcinoma c.527G>A p.C176Y 15
7 COSM45268 TP53 lung,NS,carcinoma,large cell carcinoma c.827C>A p.A276D 15
8 COSM43549 TP53 lung,NS,carcinoma,large cell carcinoma c.481G>T p.A161S 15
9 COSM10889 TP53 lung,NS,carcinoma,large cell carcinoma c.536A>G p.H179R 15
10 COSM44204 TP53 lung,NS,carcinoma,large cell carcinoma c.423C>G p.C141W 15
11 COSM43568 TP53 lung,NS,carcinoma,large cell carcinoma c.772G>T p.E258* 15
12 COSM43963 TP53 lung,NS,carcinoma,large cell carcinoma c.396G>C p.K132N 15
13 COSM10659 TP53 lung,NS,carcinoma,large cell carcinoma c.817C>T p.R273C 15
14 COSM10779 TP53 lung,NS,carcinoma,large cell carcinoma c.818G>T p.R273L 15
15 COSM6932 TP53 lung,NS,carcinoma,large cell carcinoma c.733G>A p.G245S 15
16 COSM44133 TP53 lung,NS,carcinoma,large cell carcinoma c.859G>T p.E287* 15
17 COSM3849376 TP53 lung,NS,carcinoma,large cell carcinoma c.753C>G p.I251M 15
18 COSM11514 TP53 lung,NS,carcinoma,large cell carcinoma c.1001G>T p.G334V 15
19 COSM11188 TP53 lung,NS,carcinoma,large cell carcinoma c.412G>C p.A138P 15
20 COSM10887 TP53 lung,NS,carcinoma,large cell carcinoma c.833C>G p.P278R 15
21 COSM10733 TP53 lung,NS,carcinoma,large cell carcinoma c.574C>T p.Q192* 15
22 COSM6081949 TP53 lung,NS,carcinoma,large cell carcinoma c.1060C>T p.Q354* 15
23 COSM43779 TP53 lung,NS,carcinoma,large cell carcinoma c.589G>A p.V197M 15
24 COSM44633 TP53 lung,NS,carcinoma,large cell carcinoma c.583A>T p.I195F 15
25 COSM10770 TP53 lung,NS,carcinoma,large cell carcinoma c.1045G>T p.E349* 15
26 COSM11333 TP53 lung,NS,carcinoma,large cell carcinoma c.499C>T p.Q167* 15
27 COSM44398 TP53 lung,NS,carcinoma,large cell carcinoma c.682G>A p.D228N 15
28 COSM10726 TP53 lung,NS,carcinoma,large cell carcinoma c.856G>A p.E286K 15
29 COSM11392 TP53 lung,NS,carcinoma,large cell carcinoma c.800G>C p.R267P 15
30 COSM10810 TP53 lung,NS,carcinoma,large cell carcinoma c.725G>T p.C242F 15
31 COSM10648 TP53 lung,NS,carcinoma,large cell carcinoma c.524G>A p.R175H 15
32 COSM11073 TP53 lung,NS,carcinoma,large cell carcinoma c.1024C>T p.R342* 15
33 COSM10859 TP53 lung,NS,carcinoma,large cell carcinoma c.814G>T p.V272L 15
34 COSM10941 TP53 lung,NS,carcinoma,large cell carcinoma c.730G>A p.G244S 15
35 COSM43812 TP53 lung,NS,carcinoma,large cell carcinoma c.277C>A p.L93M 15
36 COSM11323 TP53 lung,NS,carcinoma,large cell carcinoma c.482C>A p.A161D 15
37 COSM44327 TP53 lung,NS,carcinoma,large cell carcinoma c.518T>C p.V173A 15
38 COSM10654 TP53 lung,NS,carcinoma,large cell carcinoma c.637C>T p.R213* 15
39 COSM44621 TP53 lung,NS,carcinoma,large cell carcinoma c.718A>T p.S240C 15
40 COSM10646 TP53 lung,NS,carcinoma,large cell carcinoma c.725G>A p.C242Y 15
41 COSM45677 TP53 lung,NS,carcinoma,large cell carcinoma c.714T>A p.C238* 15
42 COSM44439 TP53 lung,NS,carcinoma,large cell carcinoma c.656C>T p.P219L 15
43 COSM43947 TP53 lung,NS,carcinoma,large cell carcinoma c.614A>G p.Y205C 15
44 COSM45675 TP53 lung,NS,carcinoma,large cell carcinoma c.673-1G>C p.? 15
45 COSM21593 TP53 lung,NS,carcinoma,large cell carcinoma c.358A>T p.K120* 15
46 COSM10788 TP53 lung,NS,carcinoma,large cell carcinoma c.764T>G p.I255S 15
47 COSM43626 TP53 lung,NS,carcinoma,large cell carcinoma c.475G>A p.A159T 15
48 COSM44891 TP53 lung,NS,carcinoma,large cell carcinoma c.796G>T p.G266* 15
49 COSM10750 TP53 lung,NS,carcinoma,large cell carcinoma c.490A>T p.K164* 15
50 COSM11114 TP53 lung,NS,carcinoma,large cell carcinoma c.528C>G p.C176W 15

Expression for Lung Large Cell Carcinoma

Search GEO for disease gene expression data for Lung Large Cell Carcinoma.

Pathways for Lung Large Cell Carcinoma

Pathways related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.39 ATR DDR2 EPHA3 EPHA5 FGFR1 MTOR
2
Show member pathways
12.88 DDR2 EPHA3 EPHA5 FGFR1 MTOR ROS1
3
Show member pathways
12.43 DDR2 EPHA3 EPHA5 FGFR1 MTOR
4
Show member pathways
12.27 DDR2 EPHA3 EPHA5 FGFR1 MYO18B ROS1
5 11.17 DDR2 EPHA3 EPHA5 FGFR1 ROS1

GO Terms for Lung Large Cell Carcinoma

Biological processes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.67 DDR2 EPHA3 EPHA5 ROS1
2 protein autophosphorylation GO:0046777 9.65 ATR DDR2 FGFR1 MTOR WNK3
3 protein phosphorylation GO:0006468 9.65 CASK CDC42BPB DDR2 EPHA3 EPHA5 FGFR1
4 regulation of GTPase activity GO:0043087 9.63 EPHA3 EPHA5 MTOR
5 peptidyl-tyrosine phosphorylation GO:0018108 9.63 DDR2 EPHA3 EPHA5 FGFR1 ROS1 TTN
6 positive regulation of neuron projection development GO:0010976 9.62 EPHA3 FGFR1 MTOR NME1
7 regulation of actin cytoskeleton organization GO:0032956 9.58 EPHA3 EPHA5 MTOR
8 phosphorylation GO:0016310 9.44 ATR CASK CDC42BPB DDR2 EPHA3 EPHA5
9 cardiac muscle fiber development GO:0048739 9.43 MYO18B TTN

Molecular functions related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.97 ATR CASK CDC42BPB DDR2 EPHA3 EPHA5
2 protein serine/threonine kinase activity GO:0004674 9.88 ATR CASK CDC42BPB MTOR TTN WNK3
3 protein tyrosine kinase activity GO:0004713 9.85 DDR2 EPHA3 EPHA5 FGFR1 ROS1 TTN
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.72 DDR2 EPHA3 EPHA5 FGFR1 ROS1
5 protein kinase activity GO:0004672 9.7 ATR CASK CDC42BPB DDR2 EPHA3 EPHA5
6 ephrin receptor activity GO:0005003 9.46 EPHA3 EPHA5
7 kinase activity GO:0016301 9.44 ATR CASK CDC42BPB DDR2 EPHA3 EPHA5
8 GPI-linked ephrin receptor activity GO:0005004 9.43 EPHA3 EPHA5
9 transferase activity GO:0016740 10.03 ATR CASK CDC42BPB DDR2 EPHA3 EPHA5

Sources for Lung Large Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....